Rare window on spinal muscular atrophy genetics

April 7, 2009

Caused by a mutation of the SMN gene, spinal muscular atrophy (SMA) is an infantile and juvenile neurodegenerative disorder where motor neuron loss causes progressive paralysis. A new study published in the open access journal BMC Medicine details the first research focused on human muscle tissue atrophied due to a genetic condition, and sheds light on two distinct mechanisms at work in different forms of SMA.

A research team from Italy, led by Gerolamo Lanfranchi, analyzed muscle biopsies and genomic DNA from peripheral blood of four SMA I and five SMA III patients from the Neuromuscular Bank organised by Corrado Angelini at the University of Padova, to investigate which other muscle genes, other than the SMN defect, played a role in atrophy. They used microarray and quantitative real-time PCR to study at transcriptional level the effects of a defective SMN gene in skeletal muscles affected by the two forms of SMA: the most severe, type I (infantile), and the milder type III (juvenile).

SMA type I is also known as severe infantile SMA or Werdnig-Hoffmann disease. Manifesting rapidly in infants, babies diagnosed with type I SMA do not generally live past one year of age. SMA type III represents a milder form of the disorder. It has a later onset and affected patients may be able to walk but later lose this ability.

The two forms of SMA gave distinct expression signatures. The SMA III muscle transcriptome is close to normal, whereas in SMA I is significantly altered. Genes implicated in signal transduction were up-regulated in SMA III whereas those involved in energy metabolism and muscle contraction were consistently down-regulated in SMA I.

"Our work indicates that SMA I and III muscles are in different phases: the 'prolonged' atrophic condition typical of the SMA I muscle and the coexistence of atrophy and hypertrophy in SMA III muscle," says Lanfranchi.

Previous studies have investigated transcriptional changes in mouse or rat muscle atrophied due to physiopathological conditions, but this is the first to use human tissue affected by a genetic atrophic condition.

More information: ifferent atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy , Caterina Millino, Marina Fanin, Andrea Vettori, Paolo Laveder, Maria Luisa Mostacciuolo, Corrado Angelini and Gerolamo Lanfranchi, BMC Medicine (in press), http://www.biomedc … .com/bmcmed/

Source: BioMed Central (news : web)


Rank not rated yet
Relevant PhysicsForums posts

More news stories

Team isolates nerve cells involved in storing long term memory and gene proteins associated with them

(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...

Medicine & Health / Neuroscience

created 55 minutes ago | popularity 5 / 5 (3) | comments 0 | with audio podcast report

News of plaque-clearing drug tops week of major advances against Alzheimer's disease

In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...

Medicine & Health / Diseases

created 51 minutes ago | popularity not rated yet | comments 1

To avoid early labor and delivery, weight and diet changes not the answer

One of the strongest known risk factors for spontaneous or unexpected preterm birth – any birth that occurs before the 37th week of pregnancy, most often without a known cause – is already having had one. For women ...

Medicine & Health / Health

created 4 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

Medicine & Health / Genetics

created 20 minutes ago | popularity not rated yet | comments 0

S.Africa in $208 mln AIDS drug venture with Swiss Lonza

South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

Medicine & Health / HIV & AIDS

created 1 hour ago | popularity not rated yet | comments 0


The power of estrogen -- male snakes attract other males

A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...

Could Venus be shifting gear?

(PhysOrg.com) -- ESA’s Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...

Experts reveal how plants don't get sunburn

(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.

Fool's gold may prove an unlikely alternative to overexploited catalytic materials

Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...

SLAC, Stanford team focuses on high-energy electrons to treat cancer

Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...

Unpicking HIV’s invisibility cloak

Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel target—its camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...